GSK3B and early-onset autosomal dominant Alzheimer disease: Despite these hurdles, the potential to achieve robust, disease-modifying efficacy justifies the increased effort and underscores the promise of dual GSK3β/SIRT1 targeting strategies in Alzheimer’s disease (Benek et al., 2020; Grisoni et al., 2021).